Page 189 - 2022_02-Haematologica-web

Effects of 2'MOE ASO on human platelets
Underlying immune disorder may predis- pose some transthyretin amyloidosis sub- jects to inotersen-mediated thrombocy- topenia. Nucleic Acid Ther. 2020;30(2):94- 103.
13. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580-587.
14. Flierl U, Nero TL, Lim B, et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med. 2015; 212(2):129-137.
15. Sewing S, Roth AB, Winter M, et al. Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia. PLoS One. 2017;12(11):e0187574.
16. Sewell KL, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide target- ing tumor necrosis factor-alpha. J Pharmacol Exp Ther. 2002;303(3):1334- 1343.
17. Ferrer-Marin F, Stanworth S, Josephson C, Sola-Visner M. Distinct differences in platelet production and function between neonates and adults: implications for platelet transfusion practice. Transfusion. 2013;53(11):2814-2821.
18. Vijey P, Posorske B, Machlus KR. In vitro culture of murine megakaryocytes from fetal liver-derived hematopoietic stem cells. Platelets. 2018;29(6):583-588.
19. French SL, Vijey P, Karhohs KW, et al. High Content, Label-free analysis of proplatelet production from megakaryocytes. J Thromb Haemost. 2020;18(10):2701-2711.
20. Yu RZ, Grundy JS, Geary RS. Clinical phar- macokinetics of second generation anti- sense oligonucleotides. Expert Opin Drug
Metab Toxicol. 2013;9(2):169-182.
21. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr. High-content live- cell imaging assay used to establish mecha- nism of trastuzumab emtansine (T-DM1)-- mediated inhibition of platelet production.
Blood. 2012;120(10):1975-1984.
22. Machlus KR, Wu SK, Stumpo DJ, et al.
Synthesis and dephosphorylation of MAR- CKS in the late stages of megakaryocyte maturation drive proplatelet formation. Blood. 2016;127(11):1468-1480.
23. Gaus HJ, Gupta R, Chappell AE, Ostergaard ME, Swayze EE, Seth PP. Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluores- cence polarization assay. Nucleic Acids Res. 2019;47(3):1110-1122.
24. Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019;129(1):12-23.
25. Chan MV, Leadbeater PD, Watson SP, Warner TD. Not all light transmission aggregation assays are created equal: quali- tative differences between light transmis- sion and 96-well plate aggregometry. Platelets. 2018;29(7):686-689.
26. Russell-Smith NC, Flower RJ, Cardinal DC. Measuring platelet and leucocyte aggrega- tion/adhesion responses in very small vol- umes of whole blood. J Pharmacol Methods. 1981;6(4):315-333.
27. Berton G, Mocsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol. 2005; 26(4):208-214.
28. Miller YI, Choi SH, Wiesner P, Bae YS. The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized
LDL. Br J Pharmacol. 2012;167(5):990-999. 29. Kappelmayer J, Nagy B, Jr. The Interaction of selectins and PSGL-1 as a key compo- nent in thrombus formation and cancer progression. Biomed Res Int. 2017;2017:
6138145.
30. Maugeri N, Rovere-Querini P, Evangelista
V, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P- selectin, and b2 integrin-dependent cell clearance program. Blood. 2009;113(21): 5254-5265.
31. Koupenova M, Vitseva O, MacKay CR, et al. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. Blood. 2014;124(5):791-802.
32. Ed Rainger G, Chimen M, Harrison MJ, et al. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets. 2015;26(6):507-520.
33. Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombo- cytopenia. Blood. 2019;133(19):2027-2030.
34. Crooke ST, Liang XH, Crooke RM, Baker BF, Geary RS. Antisense drug discovery and development technology considered in a pharmacological context. Biochem Pharmacol. 2020;114196.
35. Furihata K, Clemetson KJ, Deguchi H, Kunicki TJ. Variation in human platelet gly- coprotein VI content modulates glycopro- tein VI-specific prothrombinase activity. Arterioscler Thromb Vasc Biol. 2001; 21(11):1857-1863.
36. Barrachina MN, Sueiro AM, Izquierdo I, et al. GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: elucidating potential anti-atherothrombotic targets in obesity. Atherosclerosis. 2019;281:62-70.
haematologica | 2022; 107(2)
531